Artikel
Comparison of chromosomal aberrations in M0 versus M+ non-WNT/non-SHH medulloblastomas
Suche in Medline nach
Autoren
-
Tobias Goschzik
- University of Bonn Medical Center, Neuropathology, Bonn, Germany
-
Evelyn Dörner
- University of Bonn Medical Center, Neuropathology, Bonn, Germany
-
Verena Dreschmann
- University of Bonn Medical Center, Neuropathology, Bonn, Germany
-
André von Bueren
- University Medical Center Hamburg-Eppendorf, Pediatric Hematology and Oncology, Hamburg, Germany
-
Björn-Ole Juhnke
- University Medical Center Hamburg-Eppendorf, Pediatric Hematology and Oncology, Hamburg, Germany
-
Stefan Rutkowski
- University Medical Center Hamburg-Eppendorf, Pediatric Hematology and Oncology, Hamburg, Germany
-
Torsten Pietsch
- University of Bonn Medical Center, Neuropathology, Bonn, Germany
| Veröffentlicht: | 14. September 2016 |
|---|
Gliederung
Text
Introduction: Whole genome analysis of non-WNT/non-SHH medulloblastomas (MB) was performed to compare chromosomal aberrations between MB without metastases (M0) and metastatic MB (M+).
Objectives: Detection of whole chromosomal aberrations (WCA) as prognostic markers in distinct MB cohorts.
Material & Methods: DNA was extracted from FFPE material from 57 M0 and 79 M+ MB samples and used for molecular inversion profiling (Affymetrix, Santa Clara, USA). WCA were assessed using Nexus Copy Number software (BioDiscovery, El Segundo, USA).
Results: Chr. 7 gain is the most frequent WCA in both groups (M0, 49%; M+, 38%) followed by chr. X loss in the M0 group (32%) and chr. 11 loss in the M+ group (22%). In both cohorts loss of chr. 11 was associated with favourable outcome (5-year PFS: M0, 100% (n=13) vs. 71%; M+, 77% (n=17) vs. 52%). Gain of chr. 7 and loss of chr. 8 were predictive for good outcome only in the M0 group (5-year PFS: 89% (n=28) vs. 66% and 94% (n=18) vs. 69%) while chr. 10 loss indicated a better outcome in M+ patients (5-year PFS: 100% (n=7) vs. 53%). In the M0 cohort, the presence of any WCA was associated with a better outcome, but not in the M+ cohort.
Conclusion: Assessment of WCA can be used to identify prognostic chromosomal aberrations in non-WNT/non-SHH MB, but their predictive value differ between M0 and M+ patients.
